These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 18777208)

  • 1. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVP receptor antagonists in patients with CHF.
    Kumar SK; Mather PJ
    Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating hyponatremia in heart failure.
    Goldsmith SR
    Curr Cardiol Rep; 2006 May; 8(3):204-10. PubMed ID: 17552085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
    Verbalis JG
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of vasopressin antagonists.
    Costello-Boerrigter LC; Boerrigter G; Burnett JC
    Heart Fail Rev; 2009 Jun; 14(2):75-82. PubMed ID: 18766438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
    Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin receptor antagonists in heart failure.
    Thibonnier M
    Curr Opin Pharmacol; 2003 Dec; 3(6):683-7. PubMed ID: 14644024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin excess and hyponatremia.
    Pham PC; Pham PM; Pham PT
    Am J Kidney Dis; 2006 May; 47(5):727-37. PubMed ID: 16632011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
    Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
    Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP; Balk RA
    Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.